Protalix Biotherapeutics (PLX) Stock Price, Quote & News

Company Profile

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial fo...

Industry: Biotechnology

Sector: Healthcare

Phone: 201 696 9345

Website: www.protalix.com

Address:

2 University Plaza, Suite 100, Hackensack, United States

ToRni27 Jul. 15 at 11:11 AM

$PLX back to downtrend 🤪

1 · Reply

alexpitti Jul. 15 at 5:49 AM

$PLX honestly didn't know anyone cared about this company. you guys are making my interest level percolate

3 · Reply

ed29 Jul. 14 at 7:34 PM

$PLX Hoping for a shorter term horizon!

2 · Reply

ed29 Jul. 14 at 7:13 PM

$PLX Why

2 · Reply

CliffordCapital Jul. 14 at 5:25 PM

$PLX Sell algo has won 🤣😭

4 · Reply

PLX_BULLS Jul. 14 at 4:18 PM

$PLX Bold move by the Europeans to help the Ukraine! https://www.pbs.org/newshour/amp/world/ukraine-and-9-other-countries-form-coalition-to-protect-europe-from-ballistic-missiles

1 · Reply

alexpitti Jul. 14 at 2:45 PM

Meeting with $PLX ceo this week

12 · Reply

ed29 Jul. 14 at 2:40 PM

$PLX Why I love plant cells and CO2. When you understand this, then you'll understand why they waged a war against CO2. Earth's CO2 is at around 400 ppm. If it were to go down by 200, almost all life on earth would cease to exist. If it were to go up by 200, the earth would become greener, and plants 🌱 would grow bigger. We need bigger carrots!

0 · Reply

ElZocko2 Jul. 14 at 6:56 AM

$PLX if we are sitting at 2.5 or higher before ER, I will sell at least half of my position to buy back the drop afterwards as usual :D

0 · Reply

brunoq14 Jul. 14 at 4:45 AM

$PLX According to Schwab, consensus earnings for 2026 are $0.20, and $0.05 for 2027. The 2027 number is small but does not contain a milestone payment, and it is at least positive. The corporate presentation seems to suggest that there may be a sizeable milestone payment coming reasonably soon.

1 · Reply

Protalix BioTherapeutics Earnings Call Transcript: Q1 2026

May 13, 2026, 8:00 AM EDT - 2 months ago

Protalix BioTherapeutics Earnings release: Q1 2026

May 13, 2026, 8:00 AM EDT - 2 months ago

Protalix BioTherapeutics Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 2 months ago

Protalix BioTherapeutics Slides: Corporate presentation

May 13, 2026, 6:50 AM EDT - 2 months ago

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

May 6, 2026, 6:50 AM EDT - 2 months ago

Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Protalix BioTherapeutics Proxy statement: Proxy filing

Mar 18, 2026, 8:00 AM EDT - 4 months ago

Protalix BioTherapeutics Earnings Call Transcript: Q4 2025

Mar 18, 2026, 8:00 AM EDT - 4 months ago

Protalix BioTherapeutics Annual report: Q4 2025

Mar 18, 2026, 8:00 AM EDT - 4 months ago

Protalix BioTherapeutics Earnings release: Q4 2025

Mar 18, 2026, 6:50 AM EDT - 4 months ago

Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results

Mar 11, 2026, 6:50 AM EDT - 4 months ago

Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026

2026-03-09T10:16:17.000Z - 4 months ago

Protalix, Chiesi Global Rare Diseases: EC approves dosing regimen for Elfabrio

Mar 9, 2026, 6:00 AM EDT - 4 months ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)

2026-01-30T14:56:18.000Z - 5 months ago

Protalix, Chiesi Global: CHMP issues positive opinion for Elfabrio dosing

Jan 30, 2026, 9:47 AM EST - 5 months ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

Jan 30, 2026, 9:47 AM EST - 5 months ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU

Jan 5, 2026, 6:50 AM EST - 6 months ago

Protalix BioTherapeutics Letter to Stockholders

Dec 17, 2025, 6:50 AM EST - 7 months ago

Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement

2025-11-21T11:10:30.000Z - 8 months ago

Protalix price target lowered to $12 from $15 at H.C. Wainwright

Nov 13, 2025, 8:00 AM EST - 8 months ago

Protalix BioTherapeutics Earnings Call Transcript: Q3 2025

Nov 13, 2025, 8:00 AM EST - 8 months ago

Protalix BioTherapeutics Quarterly report: Q3 2025

Nov 13, 2025, 8:00 AM EST - 8 months ago

Protalix BioTherapeutics Earnings release: Q3 2025

Nov 13, 2025, 6:50 AM EST - 8 months ago

Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results

Nov 6, 2025, 6:50 AM EST - 8 months ago

Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025

Nov 3, 2025, 4:30 PM EST - 9 months ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU

2025-10-17T11:11:05.000Z - 9 months ago

Protalix, Chiesi Global: CHMP issues negative opinion for Elfabrio

Oct 17, 2025, 6:58 AM EDT - 9 months ago

Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU

Sep 16, 2025, 10:30 AM EDT - 10 months ago

Protalix BioTherapeutics Transcript: Q3 Investor Summit Group Virtual Conference 2025

Sep 11, 2025, 10:55 AM EDT - 10 months ago

Protalix BioTherapeutics to Present at Investor Summit Virtual

Sep 2, 2025, 6:50 AM EDT - 11 months ago

Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 8:30 AM EDT - 11 months ago

Protalix BioTherapeutics Earnings Call Transcript: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 11 months ago

Protalix BioTherapeutics Quarterly report: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 11 months ago

Protalix BioTherapeutics Earnings release: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 11 months ago

Protalix BioTherapeutics Registration statement: Registration Filing

Aug 14, 2025, 6:50 AM EDT - 11 months ago

Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results

Aug 7, 2025, 12:53 PM EDT - 1 year ago

Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025

2025-07-21T10:55:33.000Z - 1 year ago

Protalix appoints Gilad Mamlok as CFO

Jul 21, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer

2025-06-30T14:45:15.000Z - 1 year ago

Protalix added to Russell 3000, Russell 2000 Indexes

Jun 30, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®

May 20, 2025, 4:30 PM EDT - 1 year ago

Protalix BioTherapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 14, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

May 9, 2025, 8:30 AM EDT - 1 year ago

Protalix BioTherapeutics Earnings Call Transcript: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

Protalix BioTherapeutics Quarterly report: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

Protalix BioTherapeutics Earnings release: Q1 2025

May 9, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

May 5, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Protalix BioTherapeutics Proxy statement: Proxy Filing

2025-04-28T21:05:49.000Z - 1 year ago

Protalix files $100M mixed securities shelf

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Protalix BioTherapeutics Registration statement: Registration Filing

Mar 24, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025

2025-03-20T01:55:45.000Z - 1 year ago

Protalix Stock (PLX) Grabbing Attention with Record Revenue Surge

Mar 17, 2025, 8:30 AM EDT - 1 year ago

Protalix BioTherapeutics Earnings Call Transcript: Q4 2024

Mar 17, 2025, 8:30 AM EDT - 1 year ago

Protalix BioTherapeutics Annual report: Q4 2024

Mar 17, 2025, 8:30 AM EDT - 1 year ago

Protalix BioTherapeutics Earnings release: Q4 2024

Mar 17, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results

Mar 10, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025

Feb 4, 2025, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference

2025-02-03T11:15:19.000Z - 1 year ago

Protalix price target raised to $15 from $10 at H.C. Wainwright

Dec 23, 2024, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics Issues 2025 Letter to Stockholders

2024-12-09T12:12:11.000Z - 1 year ago

Protalix, Chiesi announce EMA validation of pegunigalsidase Variation Submission

Dec 9, 2024, 6:30 AM EST - 1 year ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa

Nov 14, 2024, 8:30 AM EST - 1 year ago

Protalix BioTherapeutics Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

Protalix BioTherapeutics Earnings release: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

Protalix BioTherapeutics Quarterly report: Q3 2024

Nov 14, 2024, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results

Nov 7, 2024, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024

Oct 25, 2024, 7:18 AM EDT - 1 year ago

Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024

Sep 17, 2024, 8:00 AM EDT - 1 year ago

Kaskela Law LLC Announces Shareholder Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm

Sep 16, 2024, 8:35 AM EDT - 1 year ago

Protalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024

Sep 4, 2024, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory Notes

Aug 14, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Earnings Call Transcript: Q2 2024

Aug 14, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Quarterly report: Q2 2024

Aug 14, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Earnings release: Q2 2024

Aug 14, 2024, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results

Aug 7, 2024, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics to Announce Second Quarter 2024 Financial and Business Results on August 14, 2024

Jun 26, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Transcript: Investor Day 2024

Jun 13, 2024, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout

May 29, 2024, 8:38 AM EDT - 2 years ago

Protalix BioTherapeutics to Present at the 2024 BIO International Convention

May 17, 2024, 8:00 AM EDT - 2 years ago

Protalix BioTherapeutics Proxy statement: Proxy Filing

May 10, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Earnings Call Transcript: Q1 2024

May 10, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Quarterly report: Q1 2024

May 10, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Earnings release: Q1 2024

May 10, 2024, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results

May 3, 2024, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Protalix BioTherapeutics Proxy statement: Proxy Filing

Mar 14, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Earnings Call Transcript: Q4 2023

Mar 14, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Annual report: Q4 2023

Mar 14, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Earnings release: Q4 2023

Mar 14, 2024, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results

Mar 7, 2024, 6:50 AM EST - 2 years ago

Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024

Feb 23, 2024, 6:50 AM EST - 2 years ago

Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference

Dec 26, 2023, 6:50 AM EST - 2 years ago

Protalix BioTherapeutics Issues 2024 Letter to Stockholders

Nov 6, 2023, 8:30 AM EST - 2 years ago

Protalix BioTherapeutics Earnings Call Transcript: Q3 2023

Nov 6, 2023, 8:30 AM EST - 2 years ago

Protalix BioTherapeutics Quarterly report: Q3 2023

Nov 6, 2023, 8:30 AM EST - 2 years ago

Protalix BioTherapeutics Earnings release: Q3 2023

Nov 6, 2023, 6:50 AM EST - 2 years ago

Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results

Oct 30, 2023, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023

ToRni27 Jul. 15 at 11:11 AM

$PLX back to downtrend 🤪

1 · Reply

alexpitti Jul. 15 at 5:49 AM

$PLX honestly didn't know anyone cared about this company. you guys are making my interest level percolate

3 · Reply

ed29 Jul. 14 at 7:34 PM

$PLX Hoping for a shorter term horizon!

2 · Reply

ed29 Jul. 14 at 7:13 PM

$PLX Why

2 · Reply

CliffordCapital Jul. 14 at 5:25 PM

$PLX Sell algo has won 🤣😭

4 · Reply

PLX_BULLS Jul. 14 at 4:18 PM

$PLX Bold move by the Europeans to help the Ukraine! https://www.pbs.org/newshour/amp/world/ukraine-and-9-other-countries-form-coalition-to-protect-europe-from-ballistic-missiles

1 · Reply

alexpitti Jul. 14 at 2:45 PM

Meeting with $PLX ceo this week

12 · Reply

ed29 Jul. 14 at 2:40 PM

0 · Reply

ElZocko2 Jul. 14 at 6:56 AM

$PLX if we are sitting at 2.5 or higher before ER, I will sell at least half of my position to buy back the drop afterwards as usual :D

0 · Reply

brunoq14 Jul. 14 at 4:45 AM

1 · Reply

jcon777 Jul. 14 at 3:04 AM

$PLX about 4 weeks until next earnings.

0 · Reply

nuDDossi Jul. 13 at 11:22 AM

$PLX was geht ab?

1 · Reply

jcon777 Jul. 13 at 3:37 AM

$PLX more AI pic fun

0 · Reply

zoomlik Jul. 12 at 3:25 AM

$PLX Added another 10k at $2.35 last week. Let’s get this party started

0 · Reply

Moneymaker03 Jul. 11 at 6:09 PM

$PLX buyout coming?

1 · Reply

CliffordCapital Jul. 11 at 6:23 AM

$PLX weekly close looking good. Good chance we hit the gap at 2.75$ soon. Just hope we don’t get the usual ER dump as always and all this slow climb was for nothing…

1 · Reply

PLX_BULLS Jul. 11 at 4:31 AM

$PLX Maybe FDA label expansion BLA submission soon. 🤷‍♂️

1 · Reply

CliffordCapital Jul. 10 at 9:59 PM

$PLX Dror and Protalix are super active recently on LinkedIn… looks like they are trying to raise awareness for the company…

2 · Reply

PLX_BULLS Jul. 10 at 8:02 PM

$PLX nice strong close!!

2 · Reply

ed29 Jul. 10 at 7:55 PM

$PLX Nothing to see here

0 · Reply

ToRni27 Jul. 10 at 7:53 PM

$PLX when $20?

0 · Reply

Artfldgr Jul. 10 at 4:21 PM

$PLX not saying anything. Just looking around...

1 · Reply

Market Cap	192.57M
Revenue (ttm)	52.74M
Net Income (ttm)	-6.60M
EPS (ttm)	N/A
PE Ratio	13.56
Forward PE	12.51
Profit Margin	-12.51%
Debt to Equity Ratio	0.00

Volume	813,400
Avg Vol	773,686
Day's Range	N/A - N/A
Shares Out	80.57M
Stochastic %K	24%
Beta	0.00
Analysts	Strong Sell
Price Target	$11.00